Clinical-Stage Companies / AGO

AGO

Pre-Approval PRO BETA

🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 6/24/2025

Total Trials

Phase 3

Phase 2

Recruiting

Score

Pipeline by Phase

Phase 3

Phase 2

Phase 1

Therapeutic Focus

Recurrent Ovarian Carcinoma Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma Recurrent Vulvar Cancer Persistent Vulvar Cancer Metastatic Vulva Cancer

Clinical Trials (7)

NCT03353831 Phase 3 COMPLETED

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

Started: 9/11/2018

NCT03690739 Phase 3 TERMINATED

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

Started: 8/9/2019

NCT01837251 Phase 3 COMPLETED

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Started: 5/1/2013

NCT05903833 Phase 2 RECRUITING

Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy

Started: 6/24/2025

NCT04644289 Phase 2 RECRUITING

WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC

Started: 5/5/2022

NCT04274426 Phase 2 ACTIVE NOT RECRUITING

Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Started: 10/13/2021

NCT05126342 Phase 2 WITHDRAWN

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Started: 11/1/2023

Drug Candidates

Mirvetuximab Soravtansine

Activity Status: Slowing

Last Trial Started: 6/24/2025

Last Trial Ended: 3/11/2025

Trials (12 months): 0

Completed Trials: 2

Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.